Working together to develop a screening platform to enhance the detection and management of Alzheimer’s disease.
PREDICTOM is an international across sector initiative to bring dementia diagnostics closer to the public through a customisable cognitive and biomarker screening platform.
Latest news
News
🧠 New Blood Test Clue in Alzheimer’s: Syndecan-3 Emerges as a Promising Biomarker
In a breakthrough that could reshape early detection of Alzheimer’s disease, researchers have identified a novel blood-based biomarker that may help distinguish Alzheimer’s patients from healthy individuals—potentially paving the way for simpler, less invasive diagnostics.
News
Over 50? Join the PREDICTOM Study and Help Advance Brain Health!
Would you like to help us understand how to reduce the risk of developing Alzheimer’s Disease?
News
PREDICTOM Launches Standardized MRI Protocol to Detect Early Alzheimer’s Risk
PREDICTOM has unveiled a standardized MRI protocol designed to identify early biomarkers of Alzheimer’s disease. With dementia cases in the EU projected to double by 2050, early detection is more critical than ever.
Did you know that you can reduce your risk of developing dementia?
The risk of developing dementia is influenced by various factors, with several of them being modifiable by the actions we take on a daily basis. On this page you can learn more about what actions you can take to reduce your risk.
Our mission
PREDICTOM will identify scalable biosignatures for early and accurate diagnosis of Alzheimer’s disease and personalized preventive interventions.